Equities research analysts forecast that INC Research Holdings, Inc. (NASDAQ:INCR) will announce sales of $586.58 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for INC Research Holdings’ earnings. The highest sales estimate is $608.44 million and the lowest is $519.21 million. INC Research Holdings reported sales of $259.56 million in the same quarter last year, which suggests a positive year over year growth rate of 126%. The business is scheduled to report its next quarterly earnings report on Monday, October 30th.

On average, analysts expect that INC Research Holdings will report full year sales of $586.58 million for the current fiscal year, with estimates ranging from $1.83 billion to $1.94 billion. For the next financial year, analysts anticipate that the company will report sales of $3.41 billion per share, with estimates ranging from $3.40 billion to $3.44 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for INC Research Holdings.

INC Research Holdings (NASDAQ:INCR) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $258.10 million during the quarter, compared to the consensus estimate of $256.76 million. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.61 EPS.

Several equities research analysts recently issued reports on INCR shares. SunTrust Banks, Inc. upgraded INC Research Holdings from a “hold” rating to a “buy” rating and upped their price target for the stock from $48.00 to $67.00 in a report on Wednesday, May 31st. KeyCorp upgraded INC Research Holdings from a “sector weight” rating to an “overweight” rating and set a $68.00 price target for the company in a report on Monday, June 5th. Jefferies Group LLC reiterated a “buy” rating and set a $62.00 price target on shares of INC Research Holdings in a report on Friday, June 16th. William Blair downgraded INC Research Holdings from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 20th. Finally, BidaskClub downgraded INC Research Holdings from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $63.79.

Shares of INC Research Holdings (INCR) opened at 54.50 on Thursday. INC Research Holdings has a 12-month low of $40.65 and a 12-month high of $61.10. The stock has a 50 day moving average price of $56.19 and a 200 day moving average price of $52.39. The firm has a market cap of $2.95 billion, a P/E ratio of 33.39 and a beta of 1.41.

In other INC Research Holdings news, CAO Christopher L. Gaenzle sold 6,873 shares of the business’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $58.32, for a total value of $400,833.36. Following the transaction, the chief accounting officer now owns 47,450 shares of the company’s stock, valued at $2,767,284. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Rush sold 41,420 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $58.26, for a total value of $2,413,129.20. Following the completion of the transaction, the chief financial officer now directly owns 42,793 shares in the company, valued at approximately $2,493,120.18. The disclosure for this sale can be found here. In the last three months, insiders sold 199,016 shares of company stock worth $11,655,556. Insiders own 0.24% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Koch Industries Inc. purchased a new position in shares of INC Research Holdings during the 2nd quarter valued at $499,000. Ameritas Investment Partners Inc. lifted its position in shares of INC Research Holdings by 483.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 20,860 shares of the company’s stock valued at $1,220,000 after buying an additional 17,284 shares during the last quarter. Castleark Management LLC purchased a new position in shares of INC Research Holdings during the 2nd quarter valued at $14,277,000. California State Teachers Retirement System lifted its position in shares of INC Research Holdings by 18.6% during the 2nd quarter. California State Teachers Retirement System now owns 96,717 shares of the company’s stock valued at $5,658,000 after buying an additional 15,179 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of INC Research Holdings by 272.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 119,772 shares of the company’s stock valued at $7,006,000 after buying an additional 87,583 shares during the last quarter. 98.97% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “$586.58 Million in Sales Expected for INC Research Holdings, Inc. (INCR) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/586-58-million-in-sales-expected-for-inc-research-holdings-inc-incr-this-quarter.html.

About INC Research Holdings

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Get a free copy of the Zacks research report on INC Research Holdings (INCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for INC Research Holdings (NASDAQ:INCR)

Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.